Risk factors for post‐transplant lymphoproliferative disease in patients with cystic fibrosis
- 25 April 2011
- journal article
- Published by Wiley in Clinical Transplantation
- Vol. 25 (4) , E430-E436
Abstract
Saueressig MG, Boussaud V, Amrein C, Guillemain R, Souilamas J, Souilamas R. Risk factors for post‐transplant lymphoproliferative disease in patients with cystic fibrosis. Clin Transplant 2011: 25: E430–E436. © 2011 John Wiley & Sons A/S.Abstract: The objective of this study was to retrospectively analyze risk factors associated with post‐transplant lymphoproliferative disease (PTLD) in a cohort of 112 lung transplant recipients with cystic fibrosis (CF). Prior to transplantation, patients were tested for Epstein–Barr virus (EBV), human herpesvirus (HHV types 1, 2, 3, 6, and 8), herpes zoster virus, and cytomegalovirus (CMV) serologies. PTLD diagnosis was established based on increased EBV viral charge plus clinical/radiographic findings and confirmed by biopsy. Negative EBV and HHV serologies at the time of lung transplantation (LTx) were significant risk factors associated with development of PTLD in patients with CF in the univariate logistic regression analysis (p < 0.05) and also in the multivariate analysis (odds ratio of 77.5 and 12.5, respectively). CMV serology, CMV mismatch, acute rejection in the first three months following LTx, HLA‐A3 antigen expression, and female gender did not affect PTLD. Our study confirmed the presence of a strong association between negative EBV serology at the time of LTx and PTLD and suggested an independent effect of negative HHV serology on PTLD.Keywords
This publication has 26 references indexed in Scilit:
- Post-transplant lymphoproliferative disorders following solid-organ transplantationExpert Review of Hematology, 2010
- The Registry of the International Society for Heart and Lung Transplantation: Twenty-sixth Official Adult Lung and Heart-Lung Transplantation Report—2009The Journal of Heart and Lung Transplantation, 2009
- Clinical outcome following lung transplantation in patients with cystic fibrosis colonised with Burkholderia cepacia complex: results from two French centresThorax, 2008
- Current understanding of the role of Epstein–Barr virus in lymphomagenesis and therapeutic approaches to EBV-associated lymphomasLeukemia & Lymphoma, 2008
- High Incidence of Posttransplant Lymphoproliferative Disease in Pediatric Patients with Cystic FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2000
- Post-Transplantation Lymphoproliferative Disorder in the Epstein-Barr Virus-Naïve Lung Transplant RecipientAmerican Journal of Respiratory and Critical Care Medicine, 1996
- Antibodies to human herpesvirus type 8 in the general population and in Kaposi's sarcoma patientsThe Lancet, 1996
- Combined lung and liver transplantation in patients with cystic fibrosis: A 4 1/2-year experienceThe Journal of Thoracic and Cardiovascular Surgery, 1995
- EPSTEIN-BARR VIRUS SEROLOGY AND EPSTEIN-BARR VIRUS-ASSOCIATED LYMPHOPROLIFERATIVE DISORDERS IN PEDIATRIC LIVER TRANSPLANT RECIPIENTSTransplantation, 1993
- An enzyme-linked immunosorbent assay for IgG antibodies to human herpes virus 6Journal of Virological Methods, 1990